AMPK: an emerging drug target for diabetes and the metabolic syndrome.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19416711.
- Also identified by DOI 10.1016/j.cmet.2009.03.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) is a key player in regulating energy metabolism, placing it at the center stage in studies of diabetes and related metabolic diseases. Expressed in key metabolically relevant organs, AMPK is activated in response to a variety of stimuli, including cellular stress, exercise, and a wide range of hormones and agents that exert impacts on cellular metabolism. Genetic and pharmacological studies demonstrate that AMPK is required for maintaining glucose homeostasis. Activation of AMPK by pharmacological agents presents a unique challenge, given the complexity of the biology, but holds a considerable potential to reverse the metabolic abnormalities associated with type 2 diabetes.
Medical subject headings
- AMP-Activated Protein Kinases
- Diabetes Mellitus, Type 2
- Metabolic Syndrome